Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 28 10 2022
accepted: 11 01 2023
pubmed: 25 2 2023
medline: 28 3 2023
entrez: 24 2 2023
Statut: ppublish

Résumé

Hypoxia is linked to disease progression and poor prognosis in several cancers, including breast cancer. Cancer cells can encounter acute, chronic, and/or intermittent periods of oxygen deprivation and it is poorly understood how the different breast cancer subtypes respond to such hypoxia regimes. Here, we assessed the response of representative cell lines for the luminal and basal A subtype to acute (24 h) and chronic hypoxia (5 days). High throughput targeted transcriptomics analysis showed that HIF-related pathways are significantly activated in both subtypes. Indeed, HIF1⍺ nuclear accumulation and activation of the HIF1⍺ target gene CA9 were comparable. Based on the number of differentially expressed genes: (i) 5 days of exposure to hypoxia induced a more profound transcriptional reprogramming than 24 h, and (ii) basal A cells were less affected by acute and chronic hypoxia as compared to luminal cells. Hypoxia-regulated gene networks were identified of which hub genes were associated with worse survival in breast cancer patients. Notably, while chronic hypoxia altered the regulation of the cell cycle in both cell lines, it induced two distinct adaptation programs in these subtypes. Mainly genes controlling central carbon metabolism were affected in the luminal cells whereas genes controlling the cytoskeleton were affected in the basal A cells. In agreement, in response to chronic hypoxia, lactate secretion was more prominently increased in the luminal cell lines which were associated with the upregulation of the GAPDH glycolytic enzyme. This was not observed in the basal A cell lines. In contrast, basal A cells displayed enhanced cell migration associated with more F-actin stress fibers whereas luminal cells did not. Altogether, these data show distinct responses to acute and chronic hypoxia that differ considerably between luminal and basal A cells. This differential adaptation is expected to play a role in the progression of these different breast cancer subtypes.

Identifiants

pubmed: 36826702
doi: 10.1007/s10549-023-06863-w
pii: 10.1007/s10549-023-06863-w
pmc: PMC10036440
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

583-596

Informations de copyright

© 2023. The Author(s).

Références

Cancer Metab. 2014 Feb 04;2(1):3
pubmed: 24491179
Int J Mol Sci. 2022 Sep 04;23(17):
pubmed: 36077517
Clin Exp Metastasis. 2021 Aug;38(4):343-359
pubmed: 34076787
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2015-2020
pubmed: 31350959
Sci Rep. 2022 Jun 3;12(1):9298
pubmed: 35665757
Nat Commun. 2022 Jul 15;13(1):4118
pubmed: 35840558
Biomed Pharmacother. 2022 Feb;146:112526
pubmed: 34906774
BMC Clin Pathol. 2013 Nov 19;13(1):30
pubmed: 24252137
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Breast Cancer Res. 2013 Jan 07;15(1):R2
pubmed: 23294542
J Physiol. 2021 Jan;599(1):23-37
pubmed: 33006160
Cancer Cell Int. 2017 May 12;17:54
pubmed: 28507454
J Clin Med. 2016 Jan 26;5(2):
pubmed: 26821054
BMC Cancer. 2020 Dec 7;20(1):1207
pubmed: 33287763
Oncogene. 2012 May 3;31(18):2283-97
pubmed: 21927022
Biomed Pharmacother. 2017 Jun;90:670-676
pubmed: 28415047
J Biol Chem. 2021 Jan-Jun;296:100369
pubmed: 33545174
Biomolecules. 2019 Aug 03;9(8):
pubmed: 31382593
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
Trends Biochem Sci. 2019 Jun;44(6):490-501
pubmed: 30655165
J Biol Chem. 2013 Apr 12;288(15):10819-29
pubmed: 23423382
Chem Res Toxicol. 2014 Mar 17;27(3):338-55
pubmed: 24450961
Sci Rep. 2017 Nov 9;7(1):15140
pubmed: 29123322
Results Probl Cell Differ. 2011;53:31-73
pubmed: 21630140
Front Oncol. 2020 Apr 08;10:486
pubmed: 32322559
Exp Cell Res. 2022 Mar 1;412(1):113006
pubmed: 34979106
Cancer Res. 2021 Oct 1;81(19):4949-4963
pubmed: 34348966
Biochem Cell Biol. 2020 Jun;98(3):386-395
pubmed: 31742425
PLoS One. 2018 Dec 4;13(12):e0208474
pubmed: 30513114
Mol Cancer Res. 2011 Jun;9(6):757-65
pubmed: 21571835
Sci Rep. 2019 Jul 15;9(1):10246
pubmed: 31308473
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54
pubmed: 20713713
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Biochem Biophys Res Commun. 2012 Mar 9;419(2):350-5
pubmed: 22342720
Mol Biol Rep. 2022 Nov;49(11):10961-10973
pubmed: 36057753
Mol Cancer Res. 2013 May;11(5):456-66
pubmed: 23378577
Drugs. 1988;36 Suppl 5:15-23
pubmed: 3076129
Sci Rep. 2017 Jun 22;7(1):4108
pubmed: 28642487
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Clin Cancer Res. 2004 Dec 15;10(24):8720-7
pubmed: 15623657
Strahlenther Onkol. 2012 Jul;188(7):616-27
pubmed: 22454045
Mol Biol Cell. 1998 Nov;9(11):3179-93
pubmed: 9802905
Genes (Basel). 2022 Sep 03;13(9):
pubmed: 36140753
Breast Cancer Res. 2019 Jan 22;21(1):10
pubmed: 30670058
Genes Genomics. 2020 Mar;42(3):317-324
pubmed: 31872384
PLoS One. 2017 May 25;12(5):e0178302
pubmed: 28542535
Front Cell Dev Biol. 2019 Jan 29;7:4
pubmed: 30761299
Oncotarget. 2017 Apr 4;8(14):23401-23413
pubmed: 28423580
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Qiuyu Liu (Q)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Nasi Liu (N)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Vera van der Noord (V)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Wanda van der Stel (W)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Bob van de Water (B)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Erik H J Danen (EHJ)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands. e.danen@lacdr.leidenuniv.nl.

Sylvia E Le Dévédec (SE)

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands. s.e.ledevedec@lacdr.leidenuniv.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH